Sugi Predict

Sugi Predict / Targets / COXFA4L2

COXFA4L2

Cytochrome c oxidase hypoxia associated subun · Q9NRX3 · COXFA4L2 on Sugi Atlas →

1,124 patent compounds predicted against COXFA4L2, 681 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15258558 SCHEMBL15258558 0.76 8/20
SCHEMBL12362713 SCHEMBL12362713 0.77 7/20
SCHEMBL15080621 SCHEMBL15080621 0.77 7/20
SCHEMBL12362702 SCHEMBL12362702 0.73 7/20
SCHEMBL14351066 SCHEMBL14351066 0.69 7/20
SCHEMBL12226742 SCHEMBL12226742 0.61 7/20
SCHEMBL12362734 SCHEMBL12362734 0.60 6/20
SCHEMBL12362700 SCHEMBL12362700 0.57 6/20
SCHEMBL13973668 SCHEMBL13973668 0.47 6/20
SCHEMBL16316892 SCHEMBL16316892 0.47 6/20
SCHEMBL24700101 SCHEMBL24700101 0.44 6/20
Auraptene Auraptene (SCHEMBL2535029) 1.00 5/20
Auraptene Auraptene (SCHEMBL2535034) 1.00 5/20
Umbelliprenin Umbelliprenin (SCHEMBL18265478) 0.98 5/20
Umbelliprenin Umbelliprenin (SCHEMBL26641528) 0.98 5/20
SCHEMBL24700226 SCHEMBL24700226 0.81 5/20
SCHEMBL12362712 SCHEMBL12362712 0.80 5/20
SCHEMBL21251480 SCHEMBL21251480 0.70 5/20
SCHEMBL25269817 SCHEMBL25269817 0.68 5/20
SCHEMBL14437596 SCHEMBL14437596 0.57 5/20

Clinical trials — most relevant to COXFA4L2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment PHASE2COMPLETED
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) PHASE2UNKNOWN
Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid Surgery PHASE1COMPLETED
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)? PHASE1UNKNOWN
Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome nanCOMPLETED
Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage nanCOMPLETED
Hypoxia-driven Prostate Cancer Genomics (HYPROGEN) nanUNKNOWN
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy nanCOMPLETED
The Genetics of Diabetes in Southern California Chinese Americans nanWITHDRAWN
Human Adaptation to High Altitude nanUNKNOWN
Gene Expression in Chronic Venous Leg Ulcers nanUNKNOWN
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine nanCOMPLETED
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells nanRECRUITING
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance nanCOMPLETED
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease nanCOMPLETED
Tissue Sample Study for Mitochondrial Disorders nanENROLLING_BY_INVITATION
Mitochondrial Dysfunction in Phelan-McDermid Syndrome nanCOMPLETED
Selecting Hypoxic Tumours for Treatment Modification nanRECRUITING
Mitochondrial Dysfunctions Driving Insulin Resistance nanCOMPLETED
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip nanCOMPLETED
A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular Powerhouse) Dysfunction nanCOMPLETED
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure nanUNKNOWN
Mitochondrial Function of Immune Cells in Sepsis nanCOMPLETED
Prediction of Outcome After Chemoradiotherapy for Head and Neck Cancer Using Functional Imaging and Tumor Biology nanUNKNOWN
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease nanCOMPLETED
Reactive Oxygen Species Following Aortic Valve Replacement nanCOMPLETED
Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a COXFA4L2 binder may also engage these)

ProteinNameSimilarity
Q4FZG9 — 0.997 Q4FZG9 →
Q3SZ44 — 0.992 Q3SZ44 →
Q4R542 — 0.990 Q4R542 →
Q3YAJ5 — 0.990 Q3YAJ5 →
Q6PBH5 — 0.987 Q6PBH5 →
Q0MQ98 — 0.987 Q0MQ98 →
Q0MQ99 — 0.985 Q0MQ99 →
COXFA4 Cytochrome c oxidase subunit NDUFA4 0.983 landscape →
Q0MQ97 — 0.983 Q0MQ97 →
Q5RK28 — 0.971 Q5RK28 →
Q62425 — 0.968 Q62425 →
Q96KJ9 — 0.968 Q96KJ9 →
Q9C002 — 0.968 Q9C002 →
Q91Y94 — 0.967 Q91Y94 →
Q8BTC1 — 0.967 Q8BTC1 →
Q810Q5 — 0.966 Q810Q5 →
Q01321 — 0.966 Q01321 →
O13085 — 0.966 O13085 →
Q91W29 — 0.965 Q91W29 →
Q68EV8 — 0.965 Q68EV8 →
Q7YRK2 — 0.965 Q7YRK2 →
Q9CPQ1 — 0.964 Q9CPQ1 →
Q7YRJ9 — 0.964 Q7YRJ9 →
Q78RX3 — 0.964 Q78RX3 →
Q0Q4Z0 — 0.963 Q0Q4Z0 →
P11951 — 0.963 P11951 →
Q9CQQ0 — 0.963 Q9CQQ0 →
COX6C Cytochrome c oxidase subunit 6C 0.963 landscape →
Q02221 — 0.963 Q02221 →
P24311 — 0.963 P24311 →